<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>11(39)</volume><submitter>Gao Q</submitter><pubmed_abstract>The clinical application of CRISPR-Cas9 remains limited by delivery challenges, particularly for oral administration. Lysine-specific demethylase 1 (&lt;i>Lsd1&lt;/i>) plays a key role in colonic inflammation and tumorigenesis. Here, we developed an oral genome-editing platform (TPGS-RNP@LNP), where &lt;i>Lsd1&lt;/i>-targeting ribonucleoproteins (RNPs) were encapsulated in mulberry leaf lipid nanoparticles (LNPs) and formulated with d-α-tocopherol polyethylene glycol succinate (TPGS). TPGS reinforced the lipid bilayer of LNPs, enhanced gastrointestinal stability, and facilitated colonic mucus penetration. Upon the galactose receptor-mediated endocytosis of TPGS-RNP@LNPs by macrophages, their fusion with the endosomal membrane and the presence of nuclear localization signals ensured the nuclear deliver</pubmed_abstract><journal>Science advances</journal><pagination>eadw9275</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12466914</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Reinforced plant-derived lipid nanoparticles for oral precise epigenome editing in colonic diseases.</pubmed_title><pmcid>PMC12466914</pmcid><pubmed_authors>Zu M</pubmed_authors><pubmed_authors>Ma S</pubmed_authors><pubmed_authors>Zhu Z</pubmed_authors><pubmed_authors>Yang K</pubmed_authors><pubmed_authors>Kundu SC</pubmed_authors><pubmed_authors>Ma Y</pubmed_authors><pubmed_authors>Reis RL</pubmed_authors><pubmed_authors>Xu H</pubmed_authors><pubmed_authors>Shi X</pubmed_authors><pubmed_authors>Gao Q</pubmed_authors><pubmed_authors>Cao Y</pubmed_authors><pubmed_authors>Gao Y</pubmed_authors><pubmed_authors>Han H</pubmed_authors><pubmed_authors>Yang Q</pubmed_authors><pubmed_authors>Liu C</pubmed_authors><pubmed_authors>Xiao B</pubmed_authors></additional><is_claimable>false</is_claimable><name>Reinforced plant-derived lipid nanoparticles for oral precise epigenome editing in colonic diseases.</name><description>The clinical application of CRISPR-Cas9 remains limited by delivery challenges, particularly for oral administration. Lysine-specific demethylase 1 (&lt;i>Lsd1&lt;/i>) plays a key role in colonic inflammation and tumorigenesis. Here, we developed an oral genome-editing platform (TPGS-RNP@LNP), where &lt;i>Lsd1&lt;/i>-targeting ribonucleoproteins (RNPs) were encapsulated in mulberry leaf lipid nanoparticles (LNPs) and formulated with d-α-tocopherol polyethylene glycol succinate (TPGS). TPGS reinforced the lipid bilayer of LNPs, enhanced gastrointestinal stability, and facilitated colonic mucus penetration. Upon the galactose receptor-mediated endocytosis of TPGS-RNP@LNPs by macrophages, their fusion with the endosomal membrane and the presence of nuclear localization signals ensured the nuclear deliver</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-06-03T21:23:46.33Z</modification><creation>2026-05-01T03:11:08.237Z</creation></dates><accession>S-EPMC12466914</accession><cross_references><pubmed>41004579</pubmed><doi>10.1126/sciadv.adw9275</doi></cross_references></HashMap>